the process of establishing and validating an in vitro method, its robustness and suitability for high throughput testing has to be assessed (Leist et al., 2012 (Leist et al., , 2010 . The U.S. National Toxicology Program (NTP) compiled a collection of 80 compounds (herein called NTP80 collection) made up of 75 unique chemicals and internal controls. The focus of this library is on known or sus-SHFWHG '1717 FRPSRXQGV DV ZHOO DV FRPSRXQGV RI VLJQL¿FDQW LQWHUHVW WR WKH 173 HJ ÀDPH UHWDUGDQWV 3$+V WKDW KDYH QRW been tested for DNT/NT activity. This library has been made available for all interested test developers with the vision to generate a comparable data matrix across many DNT and neurotoxicity assays. Initial data on the interference with iPSC differentiation, neurite outgrowth, neural crest cell migration, and cardiotoxicity have been published (Pei et al., 2016; Nyffeler et al., 2017a; Ryan et al., 2016; Sirenko et al., 2017) .
In our study, we used the NTP80 collection to evaluate the throughput and quality of the LUHMES cell-based developmental neurotoxicity assay (NeuriTox). The results from the VFUHHQ ZHUH YDOLGDWHG LQ D KLW FRQ¿UPDWLRQ SKDVH $V IROORZXS the library was also screened for peripheral nervous system toxicity (PeriTox assay; Hoelting et al., 2016) , and the data were put into context of published screens and of data available from the Tox21 program.
Material and methods

Screen library handling
The compound library was received as a 96-well "master plate" ¿OOHG ZLWK FRPSRXQGV LH D FROOHFWLRQ RI GUXJGUXJOLNH FRP-SRXQGV 3$+ SHVWLFLGHV ÀDPH UHWDUGDQWV DQG RWKHUV )LJ (Nyffeler et al., 2017a; Ryan et al., 2016; Sirenko et al., 2017) . In order to reduce freeze-thaw cycles, save compounds, and test them always after the same number of freeze-thaw cycles, sets RI ¿YH FRPSRXQGV ZHUH WUDQVIHUUHG IURP WKH ³PDVWHU SODWH´ to each "dilution plate" and diluted in DMSO. Subsequently, the dilutions were aliquoted into a "treatment plate" that was equipped with DMSO-solvent controls and narciclasine positive FRQWURO Q0 ¿QDO FRQFHQWUDWLRQ RQ FHOOV 6LJPD &$6 83-6), sealed, and stored at -80°C until use. This procedure ensured that cells were always treated with 0.1% DMSO (Fig.  S3 1 ) .
Cell culture and differentiation
For the NeuriTox test (= UKN4), LUHMES (Lund human mesencephalic) cells were characterized and cultured as described in detail earlier (Krug et al., 2013; Lotharius et al., 2005 ; Scholz HW DO %ULHÀ\ FHOOV ZHUH PDLQWDLQHG LQ SUROLIHUDWLRQ medium (PM: AdvDMEM/F12 supplemented with 2 mM glu-WDPLQH [ 1 VXSSOHPHQW DQG QJPO ¿EUREODVW JURZWK IDF-WRU LQ 3/2¿EURQHFWLQ FRDWHG ÀDVNV JPO SRO\/RUQL-WKLQH 3/2 DQG JPO ¿EURQHFWLQ )RU GLIIHUHQWLDWLRQ FHOOV were seeded at a density of 46,000 cells/cm 2 in PM. After 24 h, they were switched to differentiation medium (DM) containing DO 3ULQVHQ HW DO WKH ¿HOGV RI RUJDQ WR[LFLW\ DQG developmental toxicity still represent a major challenge (Marx et al., 2016) . Especially for neurotoxicity (NT) and developmental neurotoxicity (DNT), multiple tests have been developed, but their comparison using larger compound libraries still lags (Fritsche et al., 2017; Aschner et al., 2017; Smirnova et al., 2014) . Developmental neurotoxicity results from gestational or peripartum disturbances of neural cells that eventually lead to an altered connectivity of the neuronal system. For instance, toxicants may inhibit proliferation, differentiation or migration of neural cells (Bal-Price et al., 2015; Aschner et al., 2017) . The toxicological manifestation of disturbed key developmental processes is a structural or functional defect of the nervous system.
Current regulatory procedure hardly evaluates DNT for industrial chemicals, while about 100 pesticides have been tested according to OECD TG 426 (OECD, 2007) , which requires repeated dosing during pregnancy and lactation (Smirnova et al., 2014; van Thriel et al., 2012; Schmidt et al., 2017; Makris et al., 2009 ). This test is highly costly (ca. $1-2 million per compound), and its sensitivity has been questioned (Fritsche et al., 2017) .
At present, more than 100 compounds (including several drugs) have been found to trigger DNT in animals, while there is strong epidemiological evidence for such effects in humans for only about a dozen compounds (Aschner et al., 2017; Mundy et al., 2015; Grandjean and Landrigan, 2006) . The majority of industrial chemicals, and even of drugs, have never been evaluated for DNT Landrigan, 2006, 2014; Bennett et al., 2016; Crofton et al., 2012) . Thus, there is an enormous need for high quality and high throughput in vitro testing (Bal-Price et al., 2015; Crofton et al., 2014; Smirnova et al., 2014) .
During the last decade, in vitro tests have been developed to ¿OO WKH WHVWLQJ JDS )ULWVFKH HW DO 6FKPLGW HW DO They assess, for instance, the proliferation and differentiation of neuronal precursor cells (Baumann et al., 2016; Culbreth et al., 2012; Fritsche et al., 2005; Hogberg et al., 2010 Hogberg et al., , 2009 Schmuck et al., 2017; Shinde et al., 2017; Balmer et al., 2012) , the loss of certain neuronal (sub)populations (Baumann et al., 2016; Culbreth et al., 2012; Pamies et al., 2016; Schmuck et al., 2017; Zimmer et al., 2011b,a) , or the impairment of migration (Nyffeler et al., 2017b; Schmuck et al., 2017; Zimmer et al., 2012) , neurite outgrowth Krug et al., 2013) or neuronal network formation (Brown et al., 2017; Pamies et al., 2016; Schmuck et al., 2017) . Since a single in vitro assay cannot cover the complexity of in vivo development, plans for test strategies are built on compiling data from a battery of assays that cover all relevant processes (Fritsche et al., 2017; Zimmer et al., 2014) .
A cell source of high quality and quantity is a crucial factor for robust tests. One such option is provided by LUHMES cells. They are of human origin and represent extensively characterized neuronal progenitors that can be differentiated within six days into dopaminergic neurons (Smirnova et al., 2016; Krug et al., 2014; Scholz et al., 2011; Schildknecht et al., 2013) . In
Fig. 1: Characterization of the chemical properties of the screened library
A) The 75 unique compounds of the NTP80 collection may be classified as drug/ drug-like compounds, polycyclic aromatic hydrocarbons, pesticides, flame retardants, industrial chemicals, environmental toxicants, heavy metals, food additives, plasticizers and solvents. The numbers in the circle sectors indicate how many compounds the respective class consists of. B) The molecular weight (MW) of the compounds of the NTP80 collection was plotted against their hydrophobicity (logP). For comparison, the same plot displays the respective data for the Tox21 and DrugBank libraries. For orientation, polycyclic aromatic hydrocarbons (PAH) present in the NTP80 collection were encircled. Detailed data are given in a supplementary file 1 . C) An extensive set of molecular descriptors was generated for the combined Tox21 and DrugBank libraries (grey dots) as described in the methods section. Then, a principal component analysis (PCA) was performed and the first two PCs were used to plot the chemical space of this large compound selection (ca. 9000 compounds) in the background. The same molecular descriptors were then determined for the NTP80 compounds and their positions were marked on the PCA plot (black). The specific hits of the screen described later in this publication are highlighted in red. formed on the same pictures using combined information from H-33342 and calcein channels. Cells with normal-sized nuclei that were calcein-positive were counted as live cells, whereas H-33342 single-positive cells were counted as dead cells. Viability (V) was expressed as percentage of live cells relative to control. For calculation of the benchmark concentration values (BMC), a benchmark response (BMR) of three standard deviations of DMSO solvent controls of all assay plates (= "3 x noise level") was used. EC 50 concentrations were calculated as the concentration at which the parameter measured (neurite area or viability) GHFOLQHG WR RI WKH '062FRQWURO OHYHO 7R LGHQWLI\ VSHFL¿F effects on neurite outgrowth, the EC 50 ratio of EC 50 (viability)/ EC 50 (neurite area) was calculated. The NeuriTox test system has D VSHFL¿FLW\ WKUHVKROG UDWLR RI WKH 3HUL7R[ WHVW V\VWHP KDV RQH of 3 (Hoelting et al., 2016; Krug et al., 2013) .
'DWD DQDO\VLV FXUYH ¿WWLQJ DQG GHULYLQJ %0& and EC values
In some cases (e.g., non-toxic compounds), no EC 50 value could be calculated for viability (V). If V was not affected at the highest tested concentration (HTC), then 4 x HTC was used as surrogate EC 50 9 PDUNHG ZLWK Ƈ IRU EC 25 calculation, the HTC was doubled in this case) (Krug et al., 2013) . If the V was DIIHFWHG VLJQL¿FDQWO\ EXW E\ WKH KLJKHVW WHVWHG FRQFHQtration was taken as surrogate EC 50 (V) (marked with °). If no EC 50 for neurite area could be calculated, but neurite outgrowth ZDV LQKLELWHG VLJQL¿FDQWO\ WKH KLJKHVW WHVWHG FRQFHQWUDWLRQ ZDV taken as surrogate EC 50 (NA).
Analysis of the chemical space
The physicochemical characteristics of the ToxCast + Tox21 (called Tox21), DrugBank, and NTP80 collection chemicals were analyzed as described earlier (Nyffeler et al., 2017a) . The structures of the compounds were obtained from the SMILES provided in the original sources, converted to SDFile format (RDKit version 0.9.2 2 ) and protonated to pH 7.4 using Moka version 1.1 (Milletti et al., 2007) . The molecular weight (MW) DQG RFWDQROZDWHU GLVWULEXWLRQ FRHI¿FLHQW ORJ3 ZHUH REWDLQHG using RDKit.
The structures were normalized using standardizer 3 and converted to 3D using Corina version 3.494 (Sadowski et al., 1994) .
AdvDMEM/F12 supplemented with 2 mM glutamine, 1x N2 VXSSOHPHQW 0 WHWUDF\FOLQH P0 GLEXW\U\O ¶ ¶F\FOLF adenosine monophosphate (cAMP), and 2 ng/ml recombinant human glial cell derived neurotrophic factor (GDNF).
The PeriTox test (= UKN5) is based on cells differentiated from the H9 human embryonic stem cell (hESC) line (WA09 line), which was obtained from WiCell (Madison, WI, USA). The import of cells and the experiments were authorized under license no. Berlin, Germany) . The stem cells were cultured according to standard protocols (Thomson et al., 1998) and differentiated into immature dorsal root ganglia neurons, as described previously: after eight days of differentiation with noggin and SB-431542 (dual SMAD inhibi-WLRQ GRUVRPRUSKLQ %03 VLJQDOLQJ LQKLELWRU '$37 ȖVHFUHtase inhibitor), CHIR (Wnt antagonist) and SU (VEGF, FGF and PDGF signaling inhibitor), the neuronal precursors were cryopreserved for later use in the peripheral neurotoxicity test (PeriTox), which is described in detail in Hoelting et al. (2016) . For the PeriTox test method, the cells were thawed and seeded at a density of 100,000 cells/cm 2 LQ O 3HUL7R[ GLIIHUentiation medium (PDM) consisting of 25% KSR-S and 75% 16 PHGLD VXSSOHPHQWHG ZLWK 0 &+,5 0 68 DQG 0 '$37 RQ PDWULJHOFRDWHG SODWHV .656 knockout DMEM with 15% serum replacement, 1 x Glutamax, 1 x nonessential amino acids and 50 mM beta-mercaptoethanol; N2-S: DMEM/F12, with 2 mM Glutamax, 0.1 mg/ml DSRWUDQVIHUULQ PJPO JOXFRVH JPO LQVXOLQ P0 putrescine, 30 nM selenium, and 20 nM progesterone). After RQH KRXU O 3'0 ZLWK [ FRQFHQWUDWHG VHULDO GLOXWLRQV RI the test compounds was added to the cells. At 23 h after treatment, the cells were stained with SM and incubated for one additional hour at 37°C.
Neurotoxicity assays based on neurite outgrowth dynamics
Image acquisition was performed with an ArrayScan VTI HCS (high content imaging) microscope (Cellomics, Waltham, MA, USA).
Neurite outgrowth image analysis
The procedure was applied as detailed earlier (Hoelting et al., 2016; Stiegler et al., 2011) . After automated imaging, an algo-ULWKP ZDV DSSOLHG WKDW LGHQWL¿HG WKH QHXURQDO VRPDWD EDVHG RQ LGHQWL¿HG QXFOHL DQG VXEWUDFWHG WKH VRPDWLF DUHD IURP WKH WRWDO neuronal area to obtain the neurite area (NA), i.e., the number of SL[HOV SHU ¿HOG FRYHUHG E\ QHXULWHV 9LDELOLW\ DQDO\VLV ZDV SHU-covered only parts of the relevant chemical space, and it was over-represented in the "lower-right part" of the logP-MW plot, where the PAHs clustered.
For broader characterization of the chemical space occupied by the NTP80 collection, a large set of GRIND2 molecular descriptors was calculated for each compound. These descriptors sum up multiple chemical properties and can be considered as a comprehensive approach to characterize a compound. The same descriptors were derived for the compounds of the Tox21 and DrugBank libraries, and the latter data were displayed as a principal component analysis (PCA) scores plot. The NTP80 compounds were then projected into the same PCA scores space (Fig. 1C ). Altogether, they were spread out over a sizable area of this PCA scores map. However, it was also clear that larger screens are required to cover the chemical space more comprehensively.
Assay features and performance
In order to run the NeuriTox test in high-throughput mode, proliferating LUHMES cells were switched to medium favoring neuronal differentiation ( Fig. 2A ), and treated with the compounds. Each potential toxicant was tested at 10 concentrations that were logarithmically spaced. To monitor assay quality, several solvent control (0.1% DMSO) and positive control (50 nM narciclasine) wells were included on each test plate ( Fig. S3 1 ) . After 24 h of exposure, cells were live-stained to assess neurite outgrowth and viability at the same time. LUHMES treated with solvent control (DMSO) grew neurites, which were longer than the diameter of their somata, and the total area covered by neur-LWHV ZLWKLQ HDFK LPDJLQJ ¿HOG ZDV TXDQWL¿HG &HOOV WUHDWHG ZLWK Q0 QDUFLFODVLQH JHQHUDWHG D QHXULWH DUHD WKDW ZDV VLJQL¿cantly reduced (Fig. 2B ). As part of the standard operating pro-FHGXUH 623 DFFHSWDQFH FULWHULD ZHUH GH¿QHG WKDW GHVFULEHG the limit of variation acceptable within a plate for inclusion into data analysis. These were (i) a neurite area of at least 45,000 pixels per well (cell number and frames per well were constant) in the solvent control wells, (ii) a viability (viable cells = double positive for calcein and Hoechst) of > 90% in solvent control wells, (iii) a reduction of neurite area in cells treated with narciclasine (50 nM) by at least 25% relative to DMSO control and (iv) viability of the narciclasine-treated cells greater 90% relative to DMSO control. Analysis of these acceptance criteria across 36 test plates, run on 12 different days, showed a robust performance of the assay (Fig. 2C, D) .
Workflow for screening and data analysis of the NeuriTox test
)RU WKH DFWXDO VFUHHQLQJ SURFHGXUH D GH¿QHG ZRUNÀRZ ZDV HVtablished that contained several pre-determined decision points. All compounds were tested at 1:1000 dilutions of their stock concentration, and at subsequent 3-fold dilution levels. For most compounds, the stock was 20 mM, so that the test concentrations These were then used to generate GRIND2 descriptors (Pastor et al., 2000; Duran et al., 2009) using Pentacle software version 1.0.6 4 , with default settings. The resulting molecular descriptors were then projected into the principal component analysis (PCA) scores obtained for a collection of ca. 9000 Tox21 and DrugBank compounds ( 5 ; Wishart et al., 2008) following a sim-LODU SURFHGXUH VXSSOHPHQWDU\ ([FHO ¿OH 6 ).
Of the original 75 NTP80 collection compounds, the following four had to be removed from physicochemical analyses because they are salts or contain metallic elements not supported by our methods: (i) methylmercury (II) chloride (MeHgCl), (ii) acetic acid manganese (2+) salt, (iii) bis(tributyltin)oxide and (iv) methylcyclopentadienyl manganese tricarbonyl. For the remaining 71, logP and MW values were obtained. In the process of computing the GRIND2 molecular descriptors, two more compounds had to be removed: saccharin sodium salt hydrate DQG EHQ]REÀXRUDQWKHQH 7KXV WKH ¿QDO VHULHV SURMHFWHG LQ WKH ToxCast and Tox21 space contained 69 compounds.
Statistical analysis and data mining
The Tox21 database (retrieved via NTP Sandbox 7 ) was mined for all compounds that were active in the NeuriTox test and for which a BMC value could be calculated.
Statistics were performed using GraphPad Prism 5. Neurite RXWJURZWK GDWD ZHUH WHVWHG IRU VLJQL¿FDQFH E\ RQHZD\ $129$ IROORZHG E\ D 'XQQHWW ¶V SRVWKRF WHVW DW WKH VLJQL¿FDQFH OHYHO RI S 7KH VXPPDULHV GLVSOD\HG DUH EDVHG RQ LQGHSHQGHQW H[SHULPHQWV GLIIHUHQW FHOO ORWV XQOHVV VSHFL¿HG RWKHUZLVH DQG are termed "biological replicates".
Results and discussion
Characterization of the chemical properties of the screened library
The library (NTP80 collection) used for screening consisted RI GLIIHUHQW FRPSRXQGV RI ZKLFK ¿YH ZHUH SUHVHQW DV LQdependent duplicates. The latter were intended as internal consistency-controls, so that there were "80 compounds" to be WHVWHG 7KH WHVW LWHPV ZHUH FODVVL¿HG LQWR JURXSV DFFRUGLQJ WR their main use or chemical structure: drug/drug-like, polycyclic aromatic hydrocarbons (PAH), pesticides and plasticizers made up 72.5% of all compounds. The remaining compounds were environmental and industrial chemicals, as wells as heavy metals ( Fig. 1A and Fig. S11 ). For basic characterization of the library structure, the distribution of physicochemical properties was visualized. A plot of hydrophobicity (logP value) vs molecular weight showed that the library compounds spread out RYHU D VL]DEOH SDUW RI WKH SORW VSDFH GH¿QHG E\ RWKHU FRPSRXQGV RI WR[LFRORJLFDO FRQFHUQ KHUH H[HPSOL¿HG E\ FD FRPpounds from the ToxCast/Tox21 and DrugBank databases 5 ( Fig. 1B) (Wishart et al., 2008) . However, the NTP80 collection
Fig. 2: Assay features and performance characteristics for the NeuriTox assay in screening mode
A) Differentiation and exposure scheme used to assess neurite outgrowth inhibition of LUHMES cells. The assay was performed from the second (d2) to the third day (d3) of differentiation. To ensure a reproducible start, cells were always replated one day before the start of differentiation (d-1). They were again replated into 96-well plates on d2 and treated 1 h afterwards. Image acquisition was performed 24 h after the start of the treatment. B) Representative images of solvent and positive controls. The nuclei were stained with H-33342 and the cytoplasm was stained with calcein-AM. After automated imaging, an algorithm was applied that recognizes the nuclear area (marked in green) and the overall neuronal area. The program then identified the neuronal somata (based on identified nuclei) and subtracted the somatic area from the neuronal area to obtain the neurite area (marked in red). Viability analysis was performed on the same pictures using combined information from the H-33342 and calcein channels. Cells positive for H-33342 and calcein were counted as live cells, whereas H-33342 single-positive cells were counted as dead cells. Images on the left side have a width of 330 µm. C) To obtain data on overall robustness of the test system, the absolute neurite area and the percentage of live cells were determined for the DMSO solvent control wells of 36 test plates of different days and differentiations. One assay (= biological replicate) consisted of three technical replicate test plates, which had five similar treated DMSO wells each. The data of these five wells are displayed as single points, their mean as a horizontal line. The minimum neurite area to accept a test plate was 45,000 pixels on average per recorded well of untreated cells (orange dotted line). D) Narciclasine (50 nM) was used as positive control to establish screen acceptance standards. Five wells of cells treated with this positive control were included in each assay plate of the screen. Neurite area and viability were measured after 24 h of treatment. Values for neurite area and viability were averaged and normalized against DMSO controls. Data from 5 wells per test plate, 36 test plates and 12 different assays are displayed. The threshold for acceptance of the test plate was a mean neurite area of ) 75% of DMSO control, while mean viability had to be * 90%.
For active compounds, it was examined in a second step whether there was at least one concentration tested that affected NA VLJQL¿FDQWO\ EXW GLG QRW GHFUHDVH 9 VLJQL¿FDQWO\ ,I WKLV ZDV WKH FDVH WKH FRPSRXQG ZDV FODVVL¿HG DV D ³KLW FRPSRXQG´ &RPpounds that affected NA and V similarly at all concentrations,
ZHUH FODVVL¿HG DV XQVSHFL¿F ³F\WRWR[LF FRPSRXQGV´
)RU WKH SULPDU\ KLWV ³KLW FRPSRXQG´ KLW FRQ¿UPDWLRQ WHVWing was conducted. For that, the tested concentration range was adjusted to optimally span the estimated EC 10 , and three new independent experiments were performed. EC 50 values were calculated according to the same procedure as for the screen data. Then, the EC 50 ratio of V and NA, i.e., the offset of neurite outgrowth vs viability decrease, was calculated. These data were During the screening, each NTP80 compound was tested at 10 concentrations (plus solvent control), starting at a maximum concentration of 20 µM and then in three-fold dilutions. Altogether, the screen was performed three times (independent biological replicates). Curve fitting was performed for neurite area (NA) and viability (V). If NA or V was neither significantly different from solvent control nor altered to more than 20%, the compound was classified as inactive. Otherwise the compound was considered to be active. If active compounds affected NA at more than one concentration that did not affect V, they were classified as "hits". These were retested independently in an adjusted concentration range with subsequent curve fitting and EC50 calculation. If the EC50 ratio of V/NA was * 4, the compound was classified as a "specific (developmental) neurotoxicant". Otherwise it was classified as "cytotoxic". (Krug et al., 2013; Stiegler et al., 2011) . ,W ZDV GHYHORSHG VSHFL¿FDOO\ IRU WKLV DVVD\ DQG LW GLIIHUV L from that used for other assays of neurite growth (Harrill et al., 2013; Flaskos et al., 2011; Frimat et al., 2010; Howard et al., 2005; Yang et al., 2014) , (ii) from that of other assays that screened the same library (Ryan et al., 2016; Sirenko et al., 2017) , and (iii) even from other assays developed in our own laboratory (Nyffeler et al., 2017a) . If multiple assays are to be compared, as in the Tox21 program (Judson et al., 2014 (Judson et al., , 2016 (Judson et al., , 2015 Tice et al., 2013) or in screening the NTP80 collection, it may be advantageous to use a more generalized DOJRULWKP IRU KLW GH¿QLWLRQ 2QH VXFK DSSURDFK WDNHQ E\ WKH NTP, uses the concept of benchmark concentrations (BMC). 7KH XQGHUO\LQJ LGHD LV WKDW KLWV DUH GH¿QHG E\ WKHLU GLVWDQFH from the background noise of a given assay. In more mathematical terms, the following steps are taken: (i) the standard deviation of negative controls is determined (= background noise OHYHO %1 LL WKLV LQIRUPDWLRQ LV XVHG WR GH¿QH D EHQFKPDUN response (BMR), which follows the same rule for each assay (e.g., BMR = 3 x BN); (iii) a concentration-response curve is ¿WWHG WKURXJK WKH WHVW FRPSRXQG GDWD LY WKH LQWHUVHFWLRQ RI this curve with the BMR level is determined; (v) the concentration of the compound corresponding to this intersection-point is determined as the BMC. This procedure was applied here both for the viability and for the neurite area data obtained in the NeuriTox screen ( Fig. S4A 1 ) .
Fig. 4: Overview of NeuriTox screen results
7KH
LGHQWL¿FDWLRQ RI DFWLYH FRPSRXQGV REWDLQHG E\ WKLV %0& method was largely similar to the prediction model of the Neu-riTox assay (Fig. S4B 1 ) . Differences were only observed for the FODVVL¿FDWLRQ RI ³ERUGHUOLQH FRPSRXQGV´ LQWR F\WRWR[LF RU VSHFLIic developmental neurotoxicants. In such cases, one or the other DSSURDFK PD\ EH PRUH VHQVLWLYH RU VSHFL¿F GHSHQGLQJ RQ YDULDtions and type of uncertainty of the test data). It was obvious that DOVR WKH VHWWLQJ RI WKH VSHFL¿FLW\WKUHVKROGV DIIHFWHG KLW LGHQWL¿-FDWLRQ )RU LQVWDQFH LI VSHFL¿FLW\ RI D FRPSRXQG ZDV FODVVL¿HG by the BMC ratio (BMC V /BMC NA ), and the threshold was set at 5\DQ HW DO YDOLQRP\FLQ DQG FDUEDU\O ZHUH FODVVL¿HG as cytotoxic. If that threshold was changed to 2, the BMC method FODVVL¿HG WKH VDPH FRPSRXQGV DV VSHFL¿F '17FRPSRXQGV LQ agreement with the EC 50 method (Fig. S4B 1 ) .
7KUHH FRPSRXQGV ELVSKHQRO $ %3$ ¶ ¶WHWUDEUR-PRGLSKHQ\OHWKHU 7%'( DQG ¶ ¶ ¶SHQWDEURPRGLphenylether (PBDE) showed larger than normal data variation LQ WKH VFUHHQ $FFRUGLQJ WR WKH 1HXUL7R[ GDWD DQDO\VLV ZRUNÀRZ DOO WKUHH ZHUH LQLWLDOO\ FODVVL¿HG DV ³DFWLYH´ 7KHVH FRPSRXQGV were also active according to the BMC method. However, re-testing of BPA showed that it actually has no effect up to 0 GDWD QRW VKRZQ ZKLOH WKH RWKHUV UHWDLQHG WKH FODVVL¿-FDWLRQ DV ³XQVSHFL¿F F\WRWR[LFDQWV´ ,Q VXPPDU\ WKLV FRPSDULVRQ RI HQWLUHO\ GLIIHUHQW KLW GH¿QLWLRQ approaches showed that they mostly lead to similar results. This suggests that the test method is robust. Moreover, it shows that both approaches may be useful, depending on the intended use: used as basis for the assay prediction model. If that ratio was WKH FRPSRXQG ZDV FODVVL¿HG DV D ³VSHFL¿F GHYHORSPHQWDO neurotoxicant", while the compound was graded as a "cytotoxic FRPSRXQG´ LI WKH UDWLR ZDV )LJ
Overview of NeuriTox screen results
After testing of all "80 compounds" in three independent experiments in the NeuriTox test, concentration-response graphs were produced for subsequent data analysis. Seven compounds (valinomycin, berberine chloride, colchicine, carbaryl, diethylstilbestrol, rotenone and MPP + FDXVHG D VLJQL¿FDQW GHFUHDVH LQ neurite area at concentrations that did not affect viability ( Most cytotoxic compounds affected the neurite area and cell viability to about the same extent at any tested concentration (Fig. 4C, Fig. S5 1 ) . As methylmercury (II) chloride was present as duplicate on the master plate, it was tested twice (as compound #69 and #77). The resulting curves overlapped to a large extent, indicating assay robustness and reproducibility. EC 50 values were calculated for clear cytotoxicants directly from the screen results.
Unclear screen results were obtained only for some compounds (Fig. 4D ). In these cases, the available data were not FRQVLGHUHG VXI¿FLHQW IRU FODVVL¿FDWLRQ RI WKH UHVSHFWLYH FKHPLcal (e.g., as a neurotoxicant). Therefore, three compounds were re-tested. Captan proved to be a cytotoxicant with relatively low potency, while tebuconazole and triphenylphosphate (the latter was present twice in the library) were clearly non-toxic DW FRQFHQWUDWLRQV XS WR 0 )LJ ' )LJ 6 1 ), resulting in a toxicity EC 50 RI 0 IRU WHEXFRQD]ROH DQG ! 0 IRU triphenylphosphate, when an extended concentration range was examined.
Hit confirmation testing and hit definition in the NeuriTox test
)RU KLW FRQ¿UPDWLRQ WHVWLQJ WKH FRPSRXQGV ZHUH UHSXUFKDVHG and new stocks were prepared. Re-testing was performed using the same method, but within an optimized concentration range to facilitate EC 50 calculation. The limits to this were compound solubility and a maximum DMSO concentration of 0 Compounds that were classified as hits after the first round of screening were re-ordered independently and re-tested for their effect on neurite outgrowth inhibition (NA, orange) and viability (V, black) in an adjusted concentration range (otherwise same experimental setup as for the screening). EC values and their ratios were calculated from four-parameter log-logistic fit functions. The curves for the compounds that were classified as specific (developmental) neurotoxicants are displayed. B) Comparison of the EC50 values for neurite area and viability of the compounds that went through hit confirmation testing. If the EC50 ratio V/NA was * 4, the compound was classified as a specific (developmental) neurotoxicant (not for captan (Cap) and tebuconazole (Te)). Detailed explanations for calculations and rule sets applied in case of curves not hitting the 50% level (°, Ƈ) are given in the methods description. All data are means ± SEM from three biological replicates, dotted lines are drawn at 100% and 50%. *: p < 0.05, by one-way ANOVA followed by Dunnett's post-hoc test.
1C and Fig. S2B 1 ) . These data suggest that the NeuriTox test KDV QR REYLRXV FODVVL¿FDWLRQ ELDV ZLWK UHVSHFW WR SK\VLFRFKHPical properties.
NeuriTox hits in light of Tox21 data on these compounds
)RU DOO DFWLYH FRPSRXQGV LGHQWL¿HG IURP WKH 173 FROOHFWLRQ by the EC 50 and BMC method, available data were extracted from the Tox21 database. In order to compare data from different assays, the BMC value for the most sensitive measured endpoint was used. On this basis, the impairment of LUHMES neurite outgrowth was compared with all viability data in the Tox21 library (boxes and whiskers, n = 168 viability endpoints in total, 7-28 per compound) ( Fig. 6A ). For 11 of the 13 compared compounds, inhibition of LUHMES neurite outgrowth was more sensitive than the median response of the Tox21 assays; for 10 of the 13 compounds, LUHMES cells were even more sensitive than the 25 th percentile fraction of the Tox21 viability results. No Tox21 results were available for valinomycin and MPP + .
Furthermore, LUHMES neurite outgrowth was compared against functional endpoints (e.g., receptor activation or stress UHVSRQVH VLJQDOLQJ Q VSHFL¿F HQGSRLQWV LQ WRWDO SHU the BMC method may be more sensitive (fewer false negatives), DQG LW LV OHVV GHSHQGHQW RQ WKH SDUW RI WKH FXUYH WKDW UHÀHFWV KLJK toxicant concentrations. On the other hand, it depends greatly on the quality of the data in the low toxicity range.
Chemical characterization of specific hit compounds (= specific (developmental) neurotoxicants)
To elucidate whether the NeuriTox test has a bias to detect compounds with certain physicochemical properties, these were investigated for the set of tested compounds. Compounds that ZHUH LGHQWL¿HG DV VSHFL¿F QHXULWH RXWJURZWK LQKLELWRUV LQ WKH NeuriTox test were analyzed regarding their hydrophobicity and molecular weight (Fig. S2A 1 ) . While there was no bias for a cer-WDLQ PROHFXODU ZHLJKW GHWHFWDEOH DOO LGHQWL¿HG VSHFL¿F QHXULWH outgrowth inhibitors were located in a medium hydrophobicity range (logP values 0-5). A more generalized approach, using hundreds of chemical descriptors (GRIND2 physicochemical GHVFULSWRUV VKRZHG WKDW WKH VSHFL¿F QHXULWH RXWJURZWK LQKLEitors were evenly distributed within the physicochemical properties of the NTP80 collection compounds, and even within the chemical space of the large libraries Tox21 and DrugBank (Fig.   Fig. 6 : Comparison of NeuriTox data with Tox21 data sets A) Benchmark concentrations (BMC) were calculated as a measure for "onset of toxicity" for all active compounds across different assays. The BMC values for neurite outgrowth inhibition of LUHMES cells were in the range of the EC25 values. They were visualized together with BMC viability data of the Tox21 data set (n = 168 viability endpoints in total, 7-28 per compound). B) Comparison of the BMC for neurite outgrowth inhibition of active NeuriTox assay compounds with BMC values for specific functional endpoints (e.g., receptor activation, stress response signaling) assessed in the Tox21 screening (n = 123 specific endpoints in total, 8-16 per compound), excluding viability data, and versus a previously published neurite outgrowth test method (Ryan et al., 2016) . If no BMC could be calculated for NeuriTox or the test method reported by Ryan, it was set to 100 µM for visualization reasons. Boxes display the 25 th and 75 th percentiles as well as medians. The whiskers span from the 10 th to 90 th percentiles, data points beyond these limits are displayed as individual points.
curve shape and steepness) and they were therefore considered problematic for comparisons with other assays (e.g., the Neuri-Tox test). In order to directly compare the effects of the same set of compounds on different tests (NeuriTox vs PeriTox), the BMC(NA) values (referring more to the onset of toxicity) ZHUH SORWWHG IRU FRPSRXQGV ZKLFK ZHUH LGHQWL¿HG DV VSHFL¿F compounds in at least one of the tests (Fig. 7C ). This approach allowed the comparison of the hazard to the central nervous system (NeuriTox) vs the peripheral nervous system (PeriTox). The NeuriTox assay showed a tendency to be affected at lower compound concentrations when the compound was a hit. The PeriTox had a higher hit-rate (detection of acrylamide, iodocarb and methylmercury chloride). The PeriTox detected acrylamide, a well-known peripheral neurotoxicant (Cavanagh, 2000; Spencer and Schaumburg, 1975) , whereas the NeuriTox assay iden-WL¿HG 033 + as a hit, well in accordance with the known central nervous toxicity (Schildknecht et al., 2017) of this compound (Fig. 7C) .
)RU FRPSDULVRQ RI WKH VSHFL¿FLW\ 91$ UDWLRV RI WKH WHVWV the default prediction models have disadvantages (rules dealing, for example, with viability curves that did not drop to a 50% level). Thus, BMC values were used. This comparison shows that there are indeed some drastic differences (e.g., for MPP + ). ,W DOVR GHPRQVWUDWHV WKDW VRPH GLIIHUHQFHV LQ WKH LGHQWL¿FDWLRQ RI VSHFL¿F KLWV DUH QRW YHU\ UREXVW )RU LQVWDQFH DFU\ODPLGH re-tested at high concentration in the PeriTox and NeuriTox DVVD\V ZDV D VSHFL¿F 3HUL7R[ KLW DFFRUGLQJ WR WKH LQGLYLGXDO test prediction models. Comparison of BMC ratios suggests however, that the differences between the tests are minor. In such a borderline situation, a compound may end up by chance on either side of the hit threshold, and for some purposes, it would be useful to introduce a third category (besides hits and non-hits) of "borderline compounds" (Fig. 7D) .
The comparison also clearly shows the advantage of using two complementary assays for the same type of endpoint if VHQVLWLYLW\ RI FRPSRXQG LGHQWL¿FDWLRQ HJ IRU IXUWKHU WHVWLQJ is a major issue. The combination of both tests had a higher sensitivity for detection of potentially hazardous compounds.
Comparison of data from neurite toxicity assays with other published DNT tests
Hazardous effects of the NTP80 collection have so far been described in four publications, which span a pure cytotoxicity assessment of cells in varying neural differentiation states (Pei et al., 2016) , an alternative neurite outgrowth model (Ryan et al., 2016) , and highly function-based studies focusing on the migration of neural crest cells (Nyffeler et al., 2017a) or adverse effects on cardiomyocyte function (Sirenko et al., 2017) . These data were synoptically compared to the results of our study (Fig. 8) .
,Q WKH ¿UVW SXEOLVKHG VFUHHQ 3HL HW DO F\WRWR[LFLW\ ZDV assessed after exposure to the NTP80 collection compounds at WZR GLIIHUHQW FRQFHQWUDWLRQV DQG 0 IRU K ,Q WKLV study, many compounds appeared cytotoxic to neural cells, but KLW FRQ¿UPDWLRQ ZDV QRW SHUIRUPHG 2Q WKH RWKHU KDQG WKH FDUdiotoxicity screen (Sirenko et al., 2017) addressed a broad set of endpoints and more than half of the 69 tested compounds affect-compound) measured in the Tox21 set up, excluding viability measurements. Data from a recently published neurite outgrowth test method were included in this comparison (Ryan neurites, Ryan viability, Fig. 6B) (Ryan et al., 2016) .
For 9 of the 13 compounds, LUHMES neurite outgrowth was a more sensitive endpoint than the median of all functional Tox21 data. For all compounds, except for berberine chloride, the NeuriTox test was more sensitive than the alternative neurite outgrowth test method used by Ryan. The parkinsonian toxicant MPP + was only detected in the NeuriTox test. This is consistent with its known mode of action, which requires the dopamine transporter. The latter is expressed in LUHMES cells (Lotharius et al., 2002; Schildknecht et al., 2009) , but not in the mixed neuronal cultures used by Ryan et al. (2016) .
Re-testing of the NTP collection in the PeriTox test
We were interested in how far hits in the NeuriTox screen (hazard of compounds to central nervous system neurons) would overlap with the activity of compounds of the NTP80 collection in a recently established (Hoelting et al., 2016) test of peripheral neurotoxicity (PeriTox test). This method uses human immature dorsal root ganglia neurons (iDRG) that are produced from pluripotent stem cells that are still in a phase of neurite growth. Like in the NeuriTox assay, exposure to toxicants in this test is for 24 h, and readouts for viability (V) and neurite area (NA) are also conducted in a similar way (Fig. 7A ).
Three independent screen runs were performed, and eight FRPSRXQGV ZHUH LGHQWL¿HG DV ³DFWLYH KLW FRPSRXQGV´ DFFRUG-LQJ WR WKH HYDOXDWLRQ DOJRULWKP VSHFL¿HG DERYH IRU WKH 1HXUL7R[ test. These compounds (berberine chloride, carbaryl, colchicine, diethylstilbestrol, rotenone, valinomycin, iodocarb, and methyl-PHUFXU\ FKORULGH XQGHUZHQW VXEVHTXHQW KLW FRQ¿UPDWLRQ WHVW-LQJ 6HYHQ RI WKH HLJKW FRPSRXQGV ZHUH FRQ¿UPHG DV VSHFL¿F hits according to the published prediction model (EC 50 ratio YLDELOLW\QHXULWH DUHD +RHOWLQJ HW DO &DUEDU\O IDLOHG WKLV YHUL¿FDWLRQ VWHS )LJ % )LJ 6 1 ). After the screen, we included acrylamide in the group of hits. This is known from a IRUPHU SXEOLFDWLRQ +RHOWLQJ HW DO WR EH D VSHFL¿F DQG active compound in the PeriTox assay, but at concentrations 0 )LJ % $V IXUWKHU SRVWWHVWLQJ VWHS YDOSURLF DFLG 93$ ZDV FODVVL¿HG DV F\WRWR[LF 7KLV ZDV GRQH RQ WKH EDVLV RI previously obtained data in a much higher concentration range than used in the screen (Fig. S7 1 ) . For carbaryl and VPA, the ratio of the EC 50 YDOXHV IRU 1$ DQG 9 ZDV ! EXW :H LQYHVtigated alternative prediction models (BMCs, EC 30 , EC 25 and EC 20 ratios, Fig. S7 1 ) to explore whether they would indicate a VSHFL¿F HIIHFW RI WKH WR[LFDQWV +RZHYHU D UDWLR ! ZDV UHDFKHG by neither approach. Thus, the default prediction model appears WR \LHOG D UREXVW GH¿QLWLRQ RI KLWV DQG QRQKLWV For the PeriTox hits, the potency spanned a range from 20 nM (EC 50 (NA)) for valinomycin to 2.3 mM (EC 50 (NA)) for acrylamide. The offset between adverse effects on NA and V (EC 50 ratios) ranged from 3.2 (acrylamide) up to 330 (rotenone). These ratios were useful ranking measures within the PeriTox assay. However, they are based on various assumptions (e.g.,
Fig. 7: Comparison of the PeriTox test results with NeuriTox test hits
A) Exposure scheme for PeriTox test. Immature human dorsal root ganglia neurons were differentiated from pluripotent stem cells and frozen. For testing, cells were thawed and plated into 96-well plates (left edge of scheme). Treatment was initiated at one hour after plating. After 24 h, nuclei were stained with H-33342 and the cytoplasm was stained with calcein-AM. Then cells were imaged and an algorithm was applied that identified the neurite area and viability. Representative images of the calcein stain are shown for the different times after seeding. Image width is 175 µm. B) The NTP80 collection of compounds was screened in the PeriTox assay. Neurite area (NA, orange) and viability (V, black) were determined in at least six concentrations to identify hits. Compounds identified as hits in the PeriTox screen were re-tested and hit confirmation data are displayed. EC values and their ratios were calculated from four-parameter log-logistic fit functions. Compounds with an EC50 ratio (V/NA) * 3 were classified as specific hits in the PeriTox test. The rule set used for ratio calculations is specified in the methods section. All data are means ± SEM from three biological replicates, dotted lines are drawn at 100% and 50%. *: p < 0.05, by one-way ANOVA followed by Dunnett's post-hoc test. C) To visualize differences between central nervous (NeuriTox) and peripheral (PeriTox) neuropathy hazard, BMC values for neurite outgrowth inhibition of PeriTox were plotted against NeuriTox test BMC data. Compounds marked with # were only specific in PeriTox, whereas compounds marked with * were only specific in NeuriTox; compounds without an extra mark where specific hits in both tests. The light-blue area marks where the PeriTox test was more sensitive, whereas the light-yellow area indicates where the NeuriTox test was more sensitive. For visualization reasons, MPP + was assigned an arbitrary BMC(NA) of 1000 µM for the PeriTox test, although it was not active at all. D) Comparison of the BMC(V/NA) ratios of the compounds that were classified as specific hits in either the NeuriTox or PeriTox tests. Blue bars represent the ratios for NeuriTox, green bars for PeriTox. For visualization reasons, ratios > 5 were cut. Compounds marked with # were only specific in PeriTox, whereas compounds marked with * were only specific in NeuriTox.
Fig. 8: Cross comparison of test data for the NTP80 collection
NeuriTox (= UKN4) and PeriTox (= UKN5) data obtained here are shown in the context of published data from other test runs on the NTP80 collection. The effect of the compounds on the different tests is indicated as specific effect on cell function (blue), cytotoxic effect (red) or no effect (white); light red coloring indicates that the used assay did not discriminate between specific effects and cytotoxicity (Pei et al., 2016) . For the specific hits of the NeuriTox, PeriTox and cMINC tests (Nyffeler et al., 2017a,b) , the EC25 for the most sensitive endpoint is given in µM. For the NeuriTox test, specific hits were defined by an EC50(V/NA) ratio of * 4, for the PeriTox test the ratio had to be * 3. For the cMINC test, compounds inhibiting migration to * 25% without affecting viability by more than 10% were considered specific. For the alternative neurite outgrowth model (Ryan et al., 2016) , specificity was defined as ratio between BMC concentrations for viability and neurite area * 3.16 and the confirmation of this classification in a retesting. In the cardiotoxicity test (Sirenko et al., 2017) , compounds were defined as specific if they i) affected cardio-physiologic parameters after 30 min treatment at a three-fold lower concentration than viability and ii) if they had no effect on viability after 24 h. If not stated otherwise, NeuriTox, PeriTox and cMINC were performed with 20 µM as highest concentrations (with a DMSO concentration of 0.1%). Other assays were performed at up to 100 µM (with up to 0.5% DMSO in the test). An asterisk (*) indicates that the compound was tested at higher than standard concentrations, ° indicates that a compound was tested at lower than standard concentrations, # indicates that the calcein signal was impaired, but the authors did not conclude cytotoxicity from that. concentration would provide more comparable measures.
(iii) Different concentrations of solvent (e.g., 0.1% (v/v) DMSO (= 14 mM) or 0.5% (v/v) DMSO (= 70 mM)) can affect screen results.
(iv) Fixed concentration range screens that limit the highest possible concentration prevent testing of low potency but highly abundant compounds at relevant exposure concentrations. Examples here were VPA and acrylamide, where clinical and accidental exposure can be higher than the highest tested concentration used in our screen. The issue of test concentrations is also important in another context: how do the concentrations at which hits are observed relate to relevant in vivo concentrations? This point was neglected here, since the screen is designed to create alerts, and the follow-up evaluation would then prioritize them, e.g., taking various exposure scenarios and related estimates of human brain, plasma or fetal concentrations into account.
(v) The different false-positive rates of screens are important for comparison of screen hits or for subsequent toxicological evaluations (e.g., for QSAR or read-across approaches). In order to obtain a good sensitivity (low number of false-negatives), hit GH¿QLWLRQV RI VFUHHQV DUH VHW LQ D ZD\ WR DOORZ PDQ\ IDOVHSRV-LWLYHV )RU LQVWDQFH LI WKH VLJQL¿FDQFH OHYHO LV VHW WR WKHQ a screen of 80 compounds will result in 8 false-positives. This number can subsequently be drastically reduced by secondary re-testing of hits.
YL 2QH RI WKH PRVW SHUWLQHQW LVVXHV RI KLW GH¿QLWLRQ LV WKH test prediction model. Most screens, including NeuriTox and PeriTox, use a binary model (hit/non-hit). In such cases, threshold setting requires a large learning and training set of negative, XQVSHFL¿F DQG SRVLWLYH FRQWURO FRPSRXQGV &URIWRQ HW DO Leist et al., 2010; Schmidt et al., 2017) . For the NeuriTox and PeriTox tests, prediction models have been established based on the evaluation of the EC 50 ratio of viability and neurite area (Hoelting et al., 2016; Krug et al., 2013; Stiegler et al., 2011) . These prediction models are designed in a way that compounds that affect neurites more potently than viability (EC 50 (V/NA) ratio > 4 for NeuriTox and EC 50 (V/NA) ratio > 3 for PeriTox) DUH FRQVLGHUHG VSHFL¿F QHXURWR[LFDQWV ,W LV LPSRUWDQW WR QRWH that the prediction model only makes a statement on positives (= neurotoxicants). The model does by no means imply that compounds with a low EC 50 ratio (= non-hits) are non-toxicants. This potential fallacy must be strictly avoided. For instance, strong cytotoxicity under the given in vitro test conditions may PDVN D SRWHQWLDO VSHFL¿F in vivo neurotoxic effect.
YLL )XUWKHUPRUH LW KDV WR EH FRQVLGHUHG ZKLFK FXUYH¿WWLQJ approach and constraints were applied to yield summary data IURP WKH FXUYH¿W WR HQWHU WKHP LQWR WKH SUHGLFWLRQ PRGHO )RU instance, EC 50 YDOXHV DUH UHODWLYHO\ UREXVW DJDLQVW EDVHOLQH ÀXFtuations, but they depend strongly on the shape of the concentration response curve (shallow vs steep) and on the lower part (higher toxicity range) of the curve. In contrast, BMC values EHWWHU GH¿QH WKH DFWXDO RQVHW RI WR[LFLW\ EXW WKH\ GHSHQG VWURQJ-O\ RQ WKH ORZFRQFHQWUDWLRQ GDWD DQG EDVHOLQH ÀXFWXDWLRQV ,I WKH focus on data analysis is strong sensitivity (low false-negative rate) or comparison across many different models, the BMC is a very useful method. ed cardiomyocytes in some way. A prediction model still also needs to be developed for that test method. For our comparison, we ranked only those compounds as potentially cardiotoxic, which i) affected cardio-physiologic parameters after 30 min treatment at a three-fold lower concentration than viability and ii) if they had no effect on viability after 24 h. For the Ryan et DO QHXULWH RXWJURZWK PRGHO ZH DGRSWHG WKH FODVVL¿FD-WLRQ VXJJHVWHG E\ WKH DXWKRUV D VSHFL¿F QHXURWR[LQ KDG D %0& for neurite outgrowth that was at least 3.16-fold (= one half-log dilution step) lower than for general cytotoxicity. For the neural crest migration (cMINC) (Nyffeler et al., 2017a) as well as for the NeuriTox and PeriTox tests, the published prediction models were used (Hoelting et al., 2016; Krug et al., 2013) .
Limiting the comparison to compounds selectively active for neuro or cardio effects, the cMINC test and the cardiotoxici-W\ DVVD\ FODVVL¿HG WKH KLJKHVW QXPEHU RI FRPSRXQGV DQG UHVSHFWLYHO\ )XUWKHU DQDO\VLV RI WKH VSHFL¿F FRPSRXQGV VKRZHG WKDW QRQH RI WKH WHVWHG FRPSRXQGV HYRNHG D VSHFL¿F response in all assays. However, seven of the 69 compounds (rotenone, diethylstilbestrol, berberine chloride, valinomycin, carbaryl, methylmercury(II)chloride, and iodocarb) were active QRW QHFHVVDULO\ VSHFL¿F LQ DOO WHVW PHWKRGV ZKHQ IXOO FRQFHQtration responses were considered.
&RPSDULQJ ZKLFK FRPSRXQGV ZHUH FODVVL¿HG DV VSHFL¿F EHtween neural (NeuriTox, PeriTox, cMINC) cell based tests and the cardiotoxicity test method showed that many compounds WKDW ZHUH VSHFL¿F LQ WKH QHXURQDO V\VWHP ZHUH JHQHUDOO\ F\WRtoxic in the cardiomyocyte-based test method (e.g., rotenone, diethylstilbestrol, berberine chloride, valinomycin), whereas FRPSRXQGV WKDW ZHUH VSHFL¿F LQ WKH FDUGLRWR[LFLW\ WHVW PHWKRG were inactive or generally cytotoxic in the neuronal-based tests (e.g., carbaryl, hydroxydopamine). From this initial comparison of tests, the PeriTox and NeuriTox tests appear to have a largely RYHUODSSLQJ VSHFL¿FLW\ UDQJH 0RUHRYHU PRVW KLWV RI WKH QHX-ULWH DVVD\V DUH DOVR LGHQWL¿HG E\ WKH F0,1& WHVW +RZHYHU WKH ODWWHU WHVW LGHQWL¿HV D ODUJH JURXS RI DGGLWLRQDO FRPSRXQGV 7KH cardiotoxicity test method seems to be largely complementary.
Conclusion and outlook
Our comparative compilation of screen data shows where gaps UHPDLQ WR EH ¿OOHG LQ GDWD JHQHUDWLRQ DQG LQWHUSUHWDWLRQ )RU instance, strong developmental toxicants, such as thalidomide DQG ÀXRURXUDFLO ZHUH QRW GHWHFWHG E\ DQ\ RI WKH SXEOLVKHG screens. This pinpoints the need for supplementing the test battery with other complementary tests.
Our comparison also revealed some technical issues that need to be addressed: L 7KH GH¿QLWLRQ RI QRQDFWLYHV LV GLI¿FXOW HVSHFLDOO\ LI WKH highest tested concentration differs between screens.
(ii) The use of nominal concentrations for comparisons poses problems, as the compound concentration that impacts the cell GLUHFWO\ LV LQÀXHQFHG E\ LWV SK\VLFRFKHPLFDO SDUDPHWHUV HJ extent of adhesion to plastic and serum binding), and the properties of the test system (cell density, medium type). The free soluble concentration in the culture medium or the intracellular Knowing for which hazard assessment scenarios these tests can be applied, rationally structured test batteries can be built LQ DQ HI¿FLHQW PLQLPDO RYHUODS RI WHVWV DQG VXI¿FLHQW EURDG coverage of biological endpoints) manner.
(viii) An issue that may also need to be revisited in the future LV WKH FODVVL¿FDWLRQ RI VRFDOOHG ³ERUGHUOLQH FRPSRXQGV´ ZKHUH the EC 50 UDWLR LV FORVH WR WKH VSHFL¿FLW\ WKUHVKROG )ROORZLQJ WKH classical binary prediction model of, e.g., the NeuriTox test, a compound with an EC 50 UDWLR RI LV FODVVL¿HG DV ³F\WRWR[LF´ whereas a compound with a ratio of 4.1 is a "neurotoxicant". This sharp distinction contrasts with the statistical variation of data, e.g., in different screen runs. Therefore, it might be helpful to introduce a third category of "borderline compounds", which comprises the range around the threshold (Leontaridou et al., 2017) . Alternatively, a probability-based prediction model could be developed which is not based on distinct hazard classes LH ³QRQVSHFL¿F´ ³ERUGHUOLQH´ ³VSHFL¿F´ /HRQWDULGRX HW DO EXW ZKLFK LGHQWL¿HV WKH FRPSRXQG ¶V KD]DUG SRWHQtial (Paparella et al., 2017 (Paparella et al., , 2013 Leist et al., 2014; Basketter et al., 2012; Jaworska and Hoffmann, 2010; Hartung et al., 2013; Judson et al., 2015) . An example for such an approach is given in Fig. S8 1 EXW FRQVLGHUDEOH IXUWKHU ZRUN LV UHTXLUHG WR UH¿QH this approach.
(ix) Further issues are acceptance criteria for test data and resultant curve shapes. Here, we used "inspection by the human eye" to ensure some plausibility (e.g., monotonic curve shapes). 7KLV SURFHGXUH PD\ LQWURGXFH ELDV DQG LW LV GLI¿FXOW WR DSSO\ WR large screens. An example from the NeuriTox screen is the concentration response curve for tebuconazole ( Fig. 4D ). This compound never affected viability or neurite area more than 20% DQG LW ZRXOG WKHUHIRUH EH FODVVL¿HG DV D QRQKLW +RZHYHU YLVXal inspection showed a non-monotonic concentration-response FXUYH ,W ZDV WKHUHIRUH UHWHVWHG DQG ZDV LQGHHG LGHQWL¿HG DV DQ active cytotoxic compound (at high concentrations) ( Fig. S6 1 ) .
(x) Of toxicological concern are false negatives due to biological differences of the screen system vs the in vivo situation. A typical example here is the non-toxicity of hexane, a known neurotoxicant. In vivo, hexane is activated by P450 enzymes to hexanedione and this metabolite subsequently causes neurotoxicity. The lack of a metabolite activation system prevents the detection of such toxicants. Similarly, the in vitro system may lack important toxicant targets or the readout used can be independent of a certain target activity. An example here is acetylcholinesterase (AChE), which does not play a role for the assay readout, and thus, typically neurotoxic AChE inhibitors are not detected.
,Q RUGHU WR WUDQVLW IURP VFUHHQ KLWV WR PRUH GH¿QLWH WR[LFRlogical statements, it is usually necessary to test whether a sim-LODU DGYHUVH HIIHFW FDQ EH FRQ¿UPHG ZLWK DQRWKHU WHVW PHWKRG (= secondary hit follow-up) (Nyffeler et al., 2017a 
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Supplementary Data 1 Fig. S1 : Cross-comparison of test data for the NTP80 collection NeuriTox (= UKN4) and PeriTox (= UKN5) data obtained here are shown in the context of published data from other studies on the NTP80 collection. The effect of the chemicals on the different tests is indicated as specific effect on cell function (blue), cytotoxic effect (red), or no effect (white); light red coloring indicates that the used assay did not discriminate between specific effects and cytotoxicity ([4] = Pei et al., 2016) . For the specific hits of the UKN4, UKN5, and UKN2 (= cMINC: [1] = Nyffeler et al., 2017a) tests, the EC25 value for the most sensitive endpoint is given in µM. For the NeuriTox test, specific hits were defined by an EC50(V/NA) ratio of ≥ 4, for the PeriTox test the ratio had to be ≥ 3. For the cMINC test, compounds inhibiting migration ≥ 25% without affecting viability by more than 10% were considered specific. For the alternative neurite outgrowth model ([2] = Ryan et al., 2016) , specificity was defined as ratio between BMC concentrations for viability and neurite area ≥ 3.16 and the confirmation of this classification in a retesting. In the cardiotoxicity test ([3] =Sirenko et al., 2017), substances were defined as specific if they i) affected cardiophysiologic parameters after 30 min treatment at a three-fold lower concentration than viability and ii) if they affected viability by < 10% after 24 h. If not stated otherwise, NeuriTox, PeriTox, and cMINC were performed with 20 µM as highest concentration, with a DMSO concentration of 0.1%. Other assays were performed at concentrations up to 100 µM (with up to 0.5% DMSO in the test). Compound number in the NTP80 collection, compound classification, Chemical Abstracts Service Registry Number (CAS#), molecular weight, and hydrophobicity (logP) are given as additional information. An asterisk (*) indicates that the substance was tested at higher than standard concentrations, ° indicates that a substance was tested at lower than standard concentrations, # indicates that the calcein signal was impaired, but the authors did not conclude cytotoxicity from that. Abbreviations: PAH = polycyclic aromatic hydrocarbon, env. t./heavy metal = environmental toxicant/heavy metal.
Fig. S2: Characterization of the chemical properties of the screened library
A) Characterization of the hydrophobicity and molecular weight of the NTP80 collection chemicals. Coloring was chosen for polycyclic aromatic hydrocarbons (PAH, blue), which cluster closely together in the lower right part of the plot, and for chemicals that were identified as hits in the NeuriTox test (red). Hit substances covered the full range of molecular weights and they were in the hydrophobicity range between logP 2 and logP 5. B) An extensive set of molecular descriptors was generated for the combined Tox21 and DrugBank libraries as well as for the NTP80 collection. The chemical descriptors of the Tox21 and DrugBank libraries were used to define the axes of the principal component analysis in which the chemicals of the NTP80 collection were plotted. The specific hits of the screen described later in this publication are highlighted in redthey are spread over the complete described chemical space. C) Table of abbreviations of chemicals of the NTP80 collection.
Suppl. Fig. S3: Chemical library handling
The "master plate" of chemicals was delivered with each well (A2-H11) filled with a different chemical (75 unique chemicals plus 5 internal duplicates as control). To keep the number of freeze-thaw cycles low and equal between the experiments, five compounds from the "master plate" were always transferred to the "dilution plate", where they were diluted in DMSO and complemented with DMSO wells (solvent control) and narciclasine (50 µM on "dilution plate", 50 nM final concentration on cells, positive control). Several copies (= "aliquots") of the "dilution plates" were produced and stored at -80°C until use.
Fig. S4: Different scopes of data usage determine strategies for hit compound definitions
A) Different data usages demand alternative data evaluation procedures. For hazard identification of compounds or for quantitative follow-up (e.g., QSAR, read-across), screen hits have to be confirmed by detailed hit confirmation testing in the same assay. Moreover, confirmation in a secondary assay is desirable. For initial screening and prioritization, in the context of big data sets like Tox21, priorities are rather on rapid processing and comparability of the hit definitions across multiple diverse assays. B) Comparison of the interpretation of NeuriTox test outcomes by either the EC50 method (NeuriTox prediction model), or the BMC method. Substances that were found to be active by at least one of the methods are shown. The specificity threshold for the NeuriTox (and PeriTox) test was originally derived by statistical values from noise data in the assays (specific effect if EC50 ratio V/NA ≥ 4, Fig. 3 ). The transformation of an EC50 ratio into a BMC ratio at about the EC20 level is not trivial. Curve variability, curve steepness, and steepness-dependence of variability differ in different parts of a fitted curve. Thus, here a BMC ratio of ≥ 3.16 was used as selectivity threshold, as this value has been used in the literature (Ryan et al., 2016) . Substance classification: c= cytotoxic, s= specific hit. HIT: classified by both methods as specific hit. &: classified by both methods as cytotoxic. HIT(N): classified as active by both methods. Cytotoxic according to BMC method, specific according to NeuriTox (N) method. $: retested and classified as cytotoxic by N method; no BMC derivable. Concentrations are outside the screen range. *: BMC was derived from screen data and thus classified as cytotoxic. Retesting and EC50 analysis revealed no toxicity in the range up to 20 µM. °: Classified as active but cytotoxic by EC50 method but with EC values > 20 µM. 2,2',4,4',5-PBDE: 2,2',4,4',5pentabromdiphenylether, 2,2'4,4'-TBDE: 2,2'4,4'-tetrabromdiphenylether.
Fig. S7: Comparison of different BMC and EC values and ratios for the PeriTox test, for example substances that were classified as unspecific cytotoxicants
A) Substances that were classified as hits after the first round of screening were re-ordered independently and re-tested for their effect on neurite outgrowth inhibition (NA, orange) and viability (V, black) in an adjusted concentration range (otherwise same experimental setup as for the screening). EC values and their ratios were calculated from four-parameter log-logistic fit functions. B) EC ratios (V/NA) in the low toxicity range (EC20, EC25 or EC30) are all < 3 and thus do not classify the compounds as hits. The BMC values were calculated for the benchmark responses of 3x SD of control cells, as used by the NTP. The BMC ratio was < 3, thus supporting our classification of the compounds as non-specific toxicants. All data are means ± SEM from three biological replicates, dashed lines are drawn at 100% and 50%. *: p < 0.05, by one-way ANOVA followed by Dunnett's post-hoc test.
Suppl. Fig. S8: Exemplification of one possible hazard potential model with few example data on NeuriTox hits/non-hits
A) Graphical illustration of the fixed threshold prediction model. For values of ∆ < 4, compounds are classified as unspecific toxicants, while ∆ ≥ 4 is assumed to indicate a specific neurotoxicant. B) A set of potential curves are displayed that can relate ∆ to the hazard probability. The variation of ∆ (SD(∆)) was calculated from a large number of experiments and used to parametrize a calibration curve for a continuous prediction model of the NeuriTox assay. It is based on SD(∆) = 0.254, and assumes a log-logistic curve with upper and lower asymptotes = 0% and 100% for the transition. C) Using the curve formula displayed in B, the curve offsets (V vs NA = ∆) for various compounds measured in this study were converted to hazard probabilities. Compounds indicated in orange refer to the NeuriTox hit compounds; blue indicates compounds that had been found to be non-specific toxicants.
